Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kaoru Tsuchiya

Showing results (21-30 of 149) with videos related to

Pageof 15
Sort By:
Intervirology|June 12, 2004
A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral loadNamiki Izumi, Yasuhiro Asahina, Masayuki Kurosaki, et al.
Journal of Hepatology|August 21, 2003
Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimensYasuhiro Asahina, Namiki Izumi, Masakatsu Uchihara, et al.
Journal of Hepatology|December 4, 2003
Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype CYasuhiro Asahina, Namiki Izumi, Masakatsu Uchihara, et al.
Intervirology|March 24, 2005
Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C. Is it possible to reduce the incidence by ribanirin and IFN combination therapy?Namiki Izumi, Asahina Yasuhiro, Masayuki Kurosaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 4, 2004
Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosisJun Itakura, Namiki Izumi, Yuki Nishimura, et al.
Japanese Journal of Clinical Oncology|September 14, 2016
Early hepatocellular carcinoma as a signaling lesion for subsequent malignancyYutaka Midorikawa, Tadatoshi Takayama, Tokio Higaki, et al.
Intervirology|July 19, 2005
Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis BHiroyuki Nakanishi, Masayuki Kurosaki, Yasuhiro Asahina, et al.
Journal of Hepatology|August 16, 2005
Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis CYasuhiro Asahina, Namiki Izumi, Nobuyuki Enomoto, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 28, 2004
Differential diagnosis of hepatic nodules using delayed parenchymal phase imaging of levovist contrast ultrasound: comparative study with SPIO-MRIShiro Suzuki, Hiroko Iijima, Fuminori Moriyasu, et al.
Cancer Medicine|October 18, 2016
Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinomaHitomi Takada, Kaoru Tsuchiya, Yutaka Yasui, et al.
Pageof 15

Showing results (21-30 of 149) with videos related to

Sort By:
Pageof 15
Intervirology|June 12, 2004
A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral loadNamiki Izumi, Yasuhiro Asahina, Masayuki Kurosaki, et al.
Journal of Hepatology|August 21, 2003
Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimensYasuhiro Asahina, Namiki Izumi, Masakatsu Uchihara, et al.
Journal of Hepatology|December 4, 2003
Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype CYasuhiro Asahina, Namiki Izumi, Masakatsu Uchihara, et al.
Intervirology|March 24, 2005
Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C. Is it possible to reduce the incidence by ribanirin and IFN combination therapy?Namiki Izumi, Asahina Yasuhiro, Masayuki Kurosaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 4, 2004
Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosisJun Itakura, Namiki Izumi, Yuki Nishimura, et al.
Japanese Journal of Clinical Oncology|September 14, 2016
Early hepatocellular carcinoma as a signaling lesion for subsequent malignancyYutaka Midorikawa, Tadatoshi Takayama, Tokio Higaki, et al.
Intervirology|July 19, 2005
Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis BHiroyuki Nakanishi, Masayuki Kurosaki, Yasuhiro Asahina, et al.
Journal of Hepatology|August 16, 2005
Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis CYasuhiro Asahina, Namiki Izumi, Nobuyuki Enomoto, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 28, 2004
Differential diagnosis of hepatic nodules using delayed parenchymal phase imaging of levovist contrast ultrasound: comparative study with SPIO-MRIShiro Suzuki, Hiroko Iijima, Fuminori Moriyasu, et al.
Cancer Medicine|October 18, 2016
Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinomaHitomi Takada, Kaoru Tsuchiya, Yutaka Yasui, et al.
Pageof 15